The lack of a transfection assay, which measures inducible expression of the IL-5 promoter in response to T-cell activation signals, has greatly hampered studies of IL-5 gene regulation. In the present work, we show that stable transfection assays with the T-cell clone, D10.G4.1 and the T-cell lymphoma line, EL4.23 can be used to study the transcriptional regulation of the IL-5 promoter. We have used this assay to localize the inducible promoter/enhancer in the IL-5 gene and have demonstrated the involvement of a CTF/ NF1 site and a TCATTT-containing element in the regulatory mechanism. Mutation of this sequence motif abolished inducibility and also prevented binding of the sequence to a nuclear protein(s). A TCATTT-containing element in the proximal promoter region was also demonstrated to be essential for inducible expression of the IL-5 gene, similar to the role of this conserved element in the transcriptional regulation of the granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4 genes.
hTERLEUKIN-5 (L-5) is one of a group of cytokines produced by activated T lymphocytes that are involved in the regulation of immune and inflammatory responses. L-5 appears to play a central role in the regulation of the eosinophilia, which is characteristic of allergic diseases, such as asthma and certain parasite infections.' L-5 is also active in regulating the growth and differentiation of murine B cells? 4 IL-5 is produced by the Th2 subgroup of murine CD4+ T cells when stimulated by antigen or mitogens such as Concanavalin A ( C o d ) , but relatively little is known about the mechanisms governing its regulation. Unlike some other Tcell-produced cytokines, such as L-3, IL-4, and granulocytemacrophage colony stimulating factor (GM-CSF), the expression of IL-5 is resistant to the immunosuppressive drug cyclosporin A5 suggesting that the antigen-responsive enhancer in the IL-5 gene may be linked to the T-cell receptor via a different signalling pathway. Recent work in our laboratory has shown that IL-5 gene expression can be selectively induced in the Th2 cell clone D10G4.1 by treatment with phorbol 12-myristate 13-acetate (PMA) or by stimulation of the IL-1 receptor or CD45, without induction of the IL-3, L-4, or GM-CSF genes.6 Thus, although the IL-5 gene is part of a cytokine gene cluster on mouse chromosome 11 with L-3, L-4, and GM-CSF,' the regulation of expression of the L-5 gene must involve gene-specific mechanisms. The use of nuclear run-on transcription assays has established that the IL-5 gene in D10G4.1 cells or the T-cell lymphoma line EL4.23 is regulated primarily at the level of
The lack of a transfection assay, which measures inducible expression of the IL-5 promoter in response to T-cell activation signals, has greatly hampered studies of IL-5 gene regulation. In the present work, we show that stable transfection assays with the T-cell clone, D10.G4.1 and the T-cell lymphoma line, EL4.23 can be used to study the transcriptional regulation of the IL-5 promoter. We have used this assay to localize the inducible promoter/enhancer in the IL-5 gene and have demonstrated the involvement of a CTF/ NF1 site and a TCATTT-containing element in the regulatory mechanism. Sequencing. A IO-kb HindIII-Hind111 mouse (BALBk) DNA fragment containing the IL-5 gene was cloned into pSV2neo (pSV2neo-lOkbmIL-5G). The 3884-bp HindIII-Eco47III fragment ( Fig 1A) was sonicated and subcloned into M13.9 Sequence of M13 subclones and alkali-denatured double-stranded plasmid DNA" was obtained by the chain termination method." Both strands were completely sequenced. DNA sequences were assembled and analyzed using the programs described by Staden.l2.'' The L-5 gene 5' flanking sequence was compared with the GenBank nucleotide sequence database and databases of known motifs to identify conserved sequence elements. All L-SCAT mutants were sequenced by cycle sequencing using polymerase chain reaction (PCR).
Constructs for expression studies. The 10-kb HindIII-Hind111 IL-5 gene fragment (-3859 to +6181) was cloned into the promoterless vector pSW3 (Promega, Madison, WI) after insertion of an EcoRV linker into the BstEII site in the 3' untranslated region (creating pSP73.rnIL-SG(EcoRV)) to distinguish expression from that of the endogenous gene. The 6.5-kb Xba I-Hind111 fragment (-312 to +6181) from pSP73.mIL-SG(EcoRV) was cloned into pCEXV3I4 to create pCEXV3.mIL-SG(EcoRV).
The IL-5 gene fragment encompassing -547 to +74 was obtained by PCR using primers corresponding to the known sequence of the gene15 plus additional sequence to generate a HindIII site at its 5' end and an EcoRI site at its 3' end to facilitate cloning. This fragment was cloned into M13mp19 and its sequence confirmed. The bluntended 572-bp HindIII-Eco47III fragment was then cloned into the blunt-ended HindIII site of pSVOCAT" yielding a construct, which has 547-bp of IL-5 genomic sequence 5' of the transcriptional start From the Division of Biochemistry and Molecular Biology, John Curtin School of Medical Research, The Australian National University, Canberra, Australia.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. TTTCTTTTTT TAAGCACAGA TAAGTCTAGC TACCGCCAAT ATAGAAAAAA AAACACCCCC   TTTCCCTTTT CTCTTTGGCA GTTTGGAGCA GGGTCTTGTG TGTTCCAGAT TGAACTCACC TTTGCTGTAC ACACAAAAAA   GCCAAAGATG CTGTCACCTC TTGATCCTCC TGACTGTACC TCCCACATCT GCTGGTGTGT ACCACCACAC CTAGTAAGAT   ATTCTCAACA TTTATGTATT TTAGCCTAAC CCTGTTGGAG GTATACATTT GAATACATTT TTTCTCACTT TATCAGGAAT   TGAGTTTAAC ACATATTAAA GCAGGTGTGG GGCAGGGAGG GGGGGATAAA (CAP) site and 25-bp 3' of the CAP site (-547IL-5CAT). The largest IL-SCAT construct contained -3859 to +25 of IL-5 genomic sequence relative to the CAP site (-3859IL-5CAT) and was similarly created using the 3884-bp HindIII-Em47111 fragment from pSV2neo-lOkbmIL-5G. A number of 5' truncation mutants were obtained by restriction endonuclease digestion and religation of these two constructs. The 5' end of the IL-5 sequence in -547IL-5CAT has an Nhe I site, which was generated on ligation of the two blunt-ended HindIII ends. Double digests were performed with Nhe I and four other restriction enzymes unique to the -547-bp of IL-5 sequence. The enzymes employed were Acc I creating -458IL-5CAT, XbaI creating -312IL-5CAT, Nsi I creating -140IL-5CAT. and EcoNI creating -88IL-5CAT. Digestion of -3859IL-5CAT with Nhe I removed a fragment of 2546-bp in length and yielded -1313IL-SCAT. Nhe YSph I, and Nhe bTthl11I double digests were used to create -1170IL-5CAT and -1089IL-5CAT, respectively. These restriction enzyme sites are shown in Fig 1A. Exonuclease 111 was used to generate the remaining truncation constructs from -3859IL-5CAT using the F'romega Erase-a-Base system." -3859IL-5CAT was digested with Sac I to prevent digestion of the vector with exonuclease 111, and Age I1 (-3656) or Bgl I1 (-1483) before treatment with exonuclease I11 to generate the deletion mutants. Each construct was sequenced to determine the 5' IL-5 terminus using a 17-mer corresponding to sequence 5' of the HindIII cloning site of pSVOCAT.
The CTFVNF1 site at -940 to -928 and the T C A m site at -49 to -44 were mutated by oligonucleotide-directed in vitro mutagenesis in the -1170IL-5CAT construct. Briefly, a 1199-bp Sph I- Eco47III fragment of the IL-5 gene 5' sequence was directionally subcloned into Sph I-Sma I cut phagemid pTZ1SU (Bio-Rad, Sydney, Australia). Mutagenesis was performed in Escherichia ( E coli) strain U 1 0 3 2 (dut-, ung-)'* as described previously.'' The resulting double stranded heteroduplex phagemids were transformed into E coli strain MC1061.1 (dut+, ungC).'O Mutagenized fragments were then isolated by Sac I-Hind111 digestion, blunt-ended and cloned back into the blunt-ended HindIII cloning site of pSVOCAT. These plasmids were confirmed by sequencing. Supercoiled CsCI-purified plasmid DNA was used in transient transfection experiments. For stable transfection, L-SCAT construct DNA was linearized with Bgl I, while pMClneo PolyA DNA" was linearized with Sca I. DNA was then extracted with phenol-chloroform and ethanol precipitated before electroporation.
Reverse transcriptase-polymerase chain reaction. RNA was prepared from cells according to the method of Chomczynski and Sacchi" and cDNA prepared by conventional methods. The primers used to detect expression from pSP73.mIL-5G(EcoRV) and pCEXV-3.mIL-5G(EcoRV) were PB19 and PB26. The 5' primer PB19 (ATT-GACCGCCAAAAAGAGAAGTG) spans exons 3 and 4 in the IL-5 gene sequence and only detects mRNA. The first 15 bases of the 3' primer PB26 (GTTCAGGGTCACAGATATCGTG) correspond to the sequence of the EcoRV linker. These primers amplify a fragment of 587-bp and do not amplify endogenously expressed IL-5 mRNA. PCR reactions were analyzed on agarose gels.
Cell culture. EL4.23 and DIO.G4.1 cells were maintained in RPM1 1640 (GIBCO, Ontario, Canada) medium, 10% fetal calf serum, with the following additives: 10 mmol/L NaC1; 1 mmol/L sodium pyruvate; 62 mUL monothioglycerol; 100 U/L benzylpeni-cillin (Commonwealth Serum Laboratories [CSL], Melbourne, Australia); 100 m g L streptomycin (Sigma, St Louis, MO); 2 mmolL L-glutamine (CSL) at 3 7 T , 5% CO,, and 95% relative humidity. The RPM1 1640 medium for the T-cell clone D10.G4.1 also contained 0.05 mmoK p-mercaptoethanol (Eastman Kodak, Rochester, NY) and IL-2. The L 2 was either IO units/mL of human IL-2 (Amersham, Buckinghamshire, UK) or conditioned medium from a cell line transfected with a mouse IL-2 construct.23 DIO.G4.1 cell growth was induced by allogeneic stimulation every 10 to 14 days with irradiated spleen cells from 6 to 8 week old C57B1/6 female mice.24 D10.G4.1 cells were treated with one or more of the following as indicated: 5 pg/mL ConA, 10 nglmL PMA, 3D3 antibody" at 1 in 1, OOO dilution, 0.1 pg/mL dexamethasone or 1 pg/mL cyclosporin A. EL4.23 cells were stimulated with 10 ng/mL PMA where indicated.
Transient transfection. Cells were resuspended (at 1 X lo6 to 2 X 106/mL) in fresh medium the day before electroporation. Transfection was performed only if greater than 90% cells were alive. A total of 2 X IO' cells in complete medium were mixed with 30 pg of supercoiled IL-SCAT construct DNA in a total volume of 400 pL and electroporated using a Bio-Rad Gene Pulser and Bio-Rad Capacitance Extender. Optimum parameters were 250 V at 500 microfarad (pF) for EL4.23 and 300 V at 500 pF for DIO.G4.1. The cells were immediately transferred to 20 mL of fresh medium and allowed to recover for 16 hours. The transfected cells were divided in half and PMA was added to one half for EL4.23, or ConA for DlO.G4.1. The other half of the cells was retained as the untreated control. Cells were harvested after 12 to 16 hours for chloramphenicol acetyltransferase (CAT) analysis. The number of viable cells was routinely checked at the time of harvest.
Srable transfection. D10.G4.1 cells were electroporated 9 to 11 days after allogeneic stimulation. The day before transfection, DIO.G4.1 cells were resuspended at 1 X IO6 cells/mL, and EL4.23 cells were resuspended at 5 X IO5 cells/mL in fresh medium. Transfection was performed only if greater than 90% cells were alive. A total of 2 X IO' cells were mixed with 30 pg of linearized IL-SCAT construct and 3 pg of linearized pMC 1 neo PoIyA in 400 pL complete medium. Electrical parameters for electroporation of each cell line were the same as those for transient transfection. Immediately after electroporation, cells were transferred to 30 mL of fresh medium. D10.G4.1 cells were allogeneically stimulated the day after electroporation. Selection with the neomycin analogue G418 (400 pg/mL, GIBCO) was commenced after a further 2-day incubation. EL4.23 cells were incubated for 2 days after electroporation before commencing G418 selection (800 pg/mL). Selection with G418 was continued for 10 days, at which time all mock (no DNA) electroporated control cells were dead.
Selected polyclonal EL4.23 cells were then grown for 2 days without G418 before stimulation. The number of individual clones in the polyclonal populations was estimated from the growth rate of the transformed cell lines. The doubling time of transformed (3418-resistant EL4.23 cells was 15.5 hours and was not significantly affected by the presence of G418. By extrapolating, from cell numbers at the time of PMA stimulation, back to the day of electroporation, the number of original transfectants (and, therefore, the number of integration events after transfection) was estimated and found to vary from 350 to 1,500 for the different transfection experiments. This range is a minimum estimate of the base complexity of the polyclonal population because it assumes that the transfected cells grow immediately at their normal rate.
Selected polyclonal D10.G4.1 cells required 3 to 4 weeks growth before sufficient cells were available for the first stimulation and then a further 2 weeks growth for the duplicate stimulation. The estimation of the number of individual clones in the polycbnal populations was more difficult for these cells, as the doubling time of the cells decreased to 18 hours after allogeneic stimulation and then increased to 48 hours over the next 12 days. However, by basing the estimation on the overall growth between allogeneic stimulations (60-to 100-fold), it was possible to estimate that the minimum of number of transfectants was at least as many as estimated for EL4.23 cells.
For CAT assay of the stably transfected polyclonal cells, 1 X IO' cells were stimulated and harvested as for transiently transfected cells.
CAT assay. After decanting the cells, the tissue culture flask was rinsed once with IO mL of phosphate-buffered saline (PBS) containing 5 mmoVL EDTA, which was pooled with the culture sample. Cells were washed with PBS and then resuspended in 150 pL of 0.25 moVL Tris-HCI, pH 8.0. Samples were sonicated on ice, incubated at 65°C for 10 minutes and immediately centrifuged at 4°C for 10 minutes. The supernatant was assayed for CAT activity using the butyryl coenzyme Miquid scintillation counting (LSC) CAT a~say.2~
Gel-rerardation assay. The gel retardation assay was carried out according to the method of Singh et al." Briefly, 10 pg of nuclear extract was added to the labelled DNA in binding buffer (IO mmoVL Tris-HC1 pH 7.5, 50 mmoVL NaCI, 1 mmom DTT, 1 mmoYL EDTA, 0.05% Nonidet P-40, 5% glycerol) in a total volume of 25 p L and incubated at room temperature for 30 minutes with 15 fmol of labelled annealed oligonucleotide duplex. Poly(d1-dC).poly(dI-dC) ( l .2 pg, Pharmacia) was included as nonspecific DNA. After binding, 5 pL of the reaction mixture was loaded onto a polyacrylamide gel (6%; acrylamide:bis, 55:l) in l X TAE buffer (6.7 mmol/L Tris-HCI pH 7.5, 3.3 mmoVL sodium acetate, 1 mmoVL EDTA). The gel was preelectrophoresed in 1 X TAE for 30 minutes at 11 Vlcm, and after sample loading was electrophoresed at IS V/cm for 60 minutes at room temperature. The gel was dried and then autoradiographed.
GenRank durubuse submission. Nucleotide sequence of the S' flanking region of the mouse IL-S gene will be submitted to the GenBank database. -38591L-SCAT construct to 60 ,&transfection did not affect the result.
RESULTS

Determination
There are a few possible explanations why the -38591L-SCAT construct was not expressed after transient transfection into cell lines, which inducibly express IL-5.h.X One possible explanation is that the required regulatory elements are not present in the construct. To test if the necessary sequences are present in an intron or the 3' untranslated region of the gene, whole gene constructs were prepared. The IO-kb HindIII-Hind111 gene fragment (including 5' sequence to -3859) was modified by insertion of a linker into the BstEII site in the 3' untranslated region of the IL-5 gene and cloned into the promoterless vector pSP73 (Promega), so that the expression of the gene construct could be measured independently of that of the endogenous gene by RT-PCR. The failure of the IO-kb gene fragment to give inducible expression in transient assays suggested that either the necessary regulatory sequences were located further away from the gene, or that they do not function in the absence of the normal chromatin environment. The latter possibility was tested by stably incorporating the CAT reporter constructs into the host genome.
Demonstration of the inducible IL-S protnoter/enltnncer using stable transfection assays in DIO.G4. I cells. Stable transfection assays were performed on the different reporter gene constructs using linearized plasmid DNA cotransfected with pMC1neo PolyA. The latter plasmid carries the tleo ge'ne under the control of the herpes simplex virus thymidine kinase promoter allowing stable transfectants to be selected using (3418. Polyclonal lines consisting of a minimum of three hundred independent transfectants were generated to minimize any influence of the site of integration and copy number on expression. Copy number and expression levels in stable transfectants are often uncorrelated,3'.33 so it is not possible to completely standardize experiments of this type. Our criterion for demonstrating the presence of the IL-S enhancer was consistent high level inducible expression (minimum of IO-fold induction) in independent experiments.
When the IL-SCAT reporter constructs previously used in transient assays were stably transfected into DIOG4.I cells. the constructs carrying up to -S47
showed varying levels of constitutive expression but the -38S9IL-SCAT construct was highly inducible (Fig 2A) to the IL-3, IL-4, and GM-CSF genes, the IL-S gene is also stimulated in these cells by PMA, and its expression is resistant to inhibition by cyclosporin A." The expression of the -38S91L-SCAT construct in DlO.Ci4.I cells was also shown to have these characteristics (Fig 3) . IL-S gene expression in DIOG4.I cells is also strongly inhibited by the antiinflammatory drug dexamethasone: just a s it is in human peripheral blood mononuclear cells." Expression of the -38591L-SCAT construct induced by either ConA, 3D3 antibody, or PMA was strongly inhibited by dexamethasone (Fig 3) . However, the constitutive expression shown by the shorter constructs. such as -5471L-SCAT, was not significantly affected by dexamethasone (data not shown).
Therefore, the upstream region of the mouse IL-S gene to -3859 carries an inducible enhancer responsive to T-cell receptor stimulation and confers all of the known regulatory properties of the endogenous gene.
Loccdixrtiorl of the irlrl~rcihle IL-S prr)tno,er/enhnrIL.er LISiug EIA.23 cells. Comparative studies of the mechanisms regulating the IL-S gene and several other lymphokine genes in DIOG4.I cells and EL4.23 cells".x have shown that transcriptional regulation is predominant in both cells and that the regulatory mechanisms have very similar characteristics. EL4.23 cells were used for more detailed localization of the enhancer because these cells are much easier to cultivate and to transfect than the T-cell clone D1 OG4. I . Stable transfection assays showed that the -38S91L-SCAT construct also gave inducible expression in EL4.23 cells, whereas the expression of constructs carrying up to -S47 showed no significant inducibility (Fig 2B) . Thus, in this respect, the reporter constructs showed analogous expression characteristics in EL4.23 and DlO.Ci4.I cells, although the magnitude of expression levels relative to pRSVCAT was generally greater for the shorter constructs in EL4.23 than in D IO.G4. I cells.
A number of S' deletion constructs were prepared using existing restriction endonuclease sites or exonuclease 111 deletion as described in Materials and Methods. Stable transfection assays were performed with the aim of establishing the minimum upstream region required for inducible expression. Representative data on the localization of the enhancer B. 1 are given in Fig 4. There was some variation in the absolute level of CAT expression obtained for each construct in different experiments, as would be expected for random polyclonal populations of stable transfectants. However, the -38S91L-SCAT construct consistently gave a high level of inducible expression with inducibility greater than IO-fold, indicating the presence of the IL-S enhancer. The -38S91L-SCAT construct was used to generate four independent polyclonal lines, which showed inducibility levels of 41, 90, I S, and 82-fold respectively (Fig 2B; Fig 4B, C, and D) . In contrast, four independent polyclonal lines generated with the -5471L-SCAT construct all showed no inducibility ( Fig  2B; Fig 4A, B, and D) . Although the level of constitutive expression of the -5471L-SCAT construct was relatively high in the experiment described in Fig 2B, this was not a consistent finding. In general, the expression of this construct was much lower than the inducible expression of -38S91L-SCAT.
Initial localization experiments narrowed the functional enhancer to the region up to -1089 (Fig 4A) . Further experiments reduced the S' boundary of the enhancer to -1016 (Fig 4B and C) . In a number of separate electroporations, the polyclonal lines containing the -10161L-SCAT construct gave comparable levels of inducible expression to the -38591L-SCAT construct. In general, reporter gene constructs whose S' ends ranged from -1016 to -929 gave progressively lower levels of inducible expression (Fig 4) . Polyclonal lines containing from -S47
to -88 were not inducible ( Figs 2B and 4) . Overall, the S' deletion experiments suggest that the region -1016 to -929 carries one or more elements important in the induction of IL-S gene (Fig S) . Mutations known to prevent CTF/NFI binding': were introduced into the -1170IL-SCAT construct (Fig 6A) Comparison of the -117OIL-5CAT with the same construct containing the mutant TCATTT-containing element using stable transfections in EL4.23 cells showed that mutation of the TCATTT motif abolished inducible expression of the promoter (Fig 6B) .
DISCUSSION
Other studies in this laboratory have shown that the control of IL-5 gene expression in the T-cell clone D10.Ci4.1 and the T-cell lymphoma EL4.23 is predominantly transcriptional.".' In the present work, we have established a stable transfection assay, using either of these two cell lines, which measures IL-5 promoter activity, and we have used this assay to localize the mouse IL-5 gene transcriptional enhancer, which is responsive to stimulation of the T-cell receptor.
The proximal region of the promoter up to -547 was shown to be capable of directing constitutive expression in stable expression assays in the T-cell clone D10.G4.1. However, the effect of inclusion of additional upstream sequence to -3859 resulted in high levels of inducibility. Reporter genes carrying 3884 bases of 5' sequence (-3859 to +25), when stably transfected into D10.G4.1 cells, showed all of the known regulatory characteristics of the endogenous IL-5
Induction could be achieved with ConA, PMA, or the T-cell receptor idiotype-specific monoclonal antibody 3D3. Induction by these agents was inhibited strongly by dexamethasone, but was relatively resistant to cyclosporin A. Analogous results to those obtained with the T-cell clone D10.G4.1 were also obtained with the T-cell lymphoma EL4.23. The -3859IL-5CAT construct gave inducible expression in response to PMA stimulation, the same as for the endogenous gene,8 but only when stable transfection assays were used. Once again, the proximal region of the promoter up to -547 directed constitutive expression. In EL4.23 cells, maximal inducible expression was dependent on the presence of the region -1016 to -929. A consensus binding site for CTF/NFl was located at -940 to -928 within the critical region for inducible expression. The lower levels of inducibility of constructs -965 to -929 compared with -1016IL-5CAT may be due to a requirement for flanking sequences for cooperative interaction between transcription factors. Gel retardation assays provided evidence for the presence of a nuclear protein(s), which was capable of binding to synthetic duplex DNA corresponding to the sequence of this region. Mutation of the binding site for CTFI NF1 in a reporter gene construct (-1170IL-5CAT) resulted in loss of inducible expression, suggesting involvement of CTF/NFl in the regulatory mechanism. Although CTF/NFl has more commonly been reported to function in the proximal regions of gene promoters, it also has been shown to be active at upstream enhancer sites.".3x Our results clearly show that the CTF/NFI element at -940 to -928 is part of a distal enhancer involved in inducible expression of the IL-5 gene and that induction of the gene may involve displacement or modification of CTF/NFl.
Mutation of a conserved TCATTT-containing element in the proximal region of the promoter showed that this element was also involved in inducible expression of the IL-5 gene in EL4.23 cells. This supports analogous findings for the role of this conserved region in the inducible transcription of the human and mouse GM-CSF gene.36.39 Furthermore, a recent study has demonstrated the functional importance of the analogous element in the mouse IL-4 pr~moter.~" Responsiveness of both the GM-CSF and IL-4 promoters to Tcell activation signals appears to require other elements in addition to the intact TCATTT-containing LIS is also the case with the IL-5 gene.
Our failure to detect the inducible mouse IL-5 gene enhancer in transient transfection assays was an unexpected finding. It does not appear to be due to low transfection efficiency because transient transfection of a whole gene construct driven by the SV40 early promoter gave detectable expression, and constitutive expression of deleted IL-5 promoter constructs was observed. One possible explanation is that the antigen-responsive enhancer is active only in the highly structured chromatin environment of the chromosome, as has been established for several elements of the globin locus control region?' In a very recent study of IL-5 gene regulation using a different subline of EL4 and a reporter construct carrying 1200 bp of the promoter region, inducible promoter activity was detected in transient assays providing a combination of PMA and substances which elevate levels of intracellular CAMP was used for induction.''
The present work has provided several significant advances in approaching the study of IL-5 gene regulation. First, stable transfection of target cells was found to be necessary to obtain high level, inducible expression, which mirrored the inducible expression of the endogenous gene in every respect we were able to test. Second, using stable transfection, we were able to obtain inducible reporter gene expression in the T-cell clone D10.G4.1. This is a valuable advance, because D10.G4.1 has the relevant surface molecules and signalling pathways for a more normal induction of cytokine genes than is possible in transformed T-cell lines. Nevertheless, the T lymphoma EL4.23 cells have been useful in the dissection of the regulatory pathway. Future work will need to define any other elements necessary for regulated expression and address in detail the cooperation between distal and proximal elements in the induction of transcription. Extension of these studies to the human IL-5 gene may provide opportunities for the development of drugs that inhibit induction of IL-5 and are useful in treating allergic disease. Definition of the normal regulation mechanisms also may allow investigation of possible abnormal IL-5 regulation in disorders involving eosinophilia, such as the hypereosinophilic syndrome.44
